---
document_datetime: 2023-09-21 20:45:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/akynzeo-epar-all-authorised-presentations_en.pdf
document_name: akynzeo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9203264
conversion_datetime: 2025-12-28 03:43:54.504217
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength         | Pharmaceutical Form                              | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                  |
|------------------|-------------------|------------------|--------------------------------------------------|---------------------------|-----------------------|---------------------------|----------------------------|
| EU/1/15/1001/001 | Akynzeo           | 300 mg / 0.50 mg | Capsule, hard                                    | Oral use                  | blister (alu/alu)     |                           | 1 capsule                  |
| EU/1/15/1001/002 | Akynzeo           | 300 mg / 0.50 mg | Capsule, hard                                    | Oral use                  | blister (alu/alu)     |                           | 4 x 1 capsules (unit dose) |
| EU/1/15/1001/003 | Akynzeo           | 235 mg / 0.25 mg | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          |                           | 1 vial                     |
| EU/1/15/1001/004 | Akynzeo           | 235 mg / 0.25 mg | Concentrate for solution for infusion            | Intravenous use           | vial (glass)          | 20 ml                     | 1 vial                     |